

Where We Are

We create innovations that bring hope to each individual patient and deliver value globally.

Enhertu treated patients

Cumulative total of approximately
94,650 patients

Our products are delivered to cancer patients worldwide, serving as a treatment option in 69 countries and regions.

Revenue

¥1,886.3 billion

Our sales have grown approximately twofold over the past three years. With overseas sales accounting for over 60%, we are expanding our business globally.

R&D expenses

¥432.9 billion

We are actively pursuing strategic investments in our research and development infrastructure to continuously generate innovations, focusing on maximizing the value of our key pipeline including 5 DXd ADCs and creating next-generation innovative pharmaceuticals.

ROE

17.9%

We maintain a high level of ROE (Return on Equity) within the industry, and with a core operating profit margin before R&D expenses of 39.5%, we ensure high profitability.

Number of employees

19,765

Employees dedicated to creating and delivering medicines for patients. We operate globally across 32 countries and regions.

* The five figures presented are based on data as of fiscal year 2024.

Where We Came from

We have continuously created innovative pharmaceuticals and responded to the unmet medical needs of each era.

1899

■ Digestive enzyme preparation
Takadiastase®

1989

■ Hypercholesterolemia treatment
Mevalotin®

1993

■ Broad-spectrum oral antibacterial agent
Cravit®

2002

■ Antihypertensive drug
Olmetec®

2009

■ Antiplatelet agent
Effient®

2010

■ Anti-influenza drug
Inavir®

2011

■ Anticoagulant
Lixiana®

2019

■ Pain management drug
Tarlige®

Hypertension treatment
Minnebro®

2020

■ Anticancer drug
Enhertu®

2022

■ Anticancer drug
Ezharmia®

2023

■ COVID-19 vaccine
DAICHIRONA®
Intramuscular Injection

2024

■ Anticancer drug
Datroway®

What Makes Us Grow



We have key growth drivers that will enable us to realize our 2030 Vision.

Science & Technology (S&T)

Drug discovery capabilities that create innovation, and a DNA that inherits challenges

P 27

We create breakthrough innovations centered on our R&D DNA and culture inherited as a drug discovery company, and unique technological capabilities, exemplified by DXd ADC technology.

Human Resources

People grow, the organization thrive

P 33

Positioning “people” as the source of value creation, we develop competitive talent and promote building a strong global organization through strengthening human capital.

Patient Centricity

Value creation starting from patients

P 39

We place Patient Centricity at the foundation of all corporate activities, with all employees united by shared values to contribute to more patients more quickly.

Where We Go

2030 Vision

An Innovative Global Healthcare
Company Contributing to the
Sustainable Development of Society

- 1 Deliver “hope” to patients
- 2 Aim to be a Global Top 10 Oncology company,
bringing innovation from Japan to the world
- 3 Contribute to sustainable social development
together with diverse stakeholders

We will continue to take on challenges to contribute to the
enrichment of quality of life around the world.